Pharmacotherapy of perinatal HIV

Seminars in Fetal and Neonatal Medicine

Volumn 10, Issue 2, 2005, Pages 161-175

  Capparelli, Edmund ^a   Rakhmanina, Natella ^b   Mirochnick, Mark ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HIV agents; Breast feeding; Didanosine; Disease transmission; Efavirenz; Female; HIV infections; Human; Indinavir; Infant; Lamivudine; Nelfinavir; Nevirapine; Newborn; Pharmacokinetics; Pregnancy; Ritonavir; Saquinavir; Stavudine; Zidovudine

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZALCITABINE; ZIDOVUDINE;

BONE MARROW SUPPRESSION; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONGENITAL MALFORMATION; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER NECROSIS; LIVER TOXICITY; LOW BIRTH WEIGHT; NAUSEA; NEPHROTOXICITY; NONHUMAN; OSTEOMALACIA; PATIENT EDUCATION; PERINATAL INFECTION; PREGNANCY; PREMATURE LABOR; PREMATURITY; REVIEW; SIDE EFFECT; SKIN ALLERGY; TERATOGENESIS; TOXICITY; TREATMENT FAILURE; VIRUS REPLICATION; VIRUS TRANSMISSION; VOMITING;

EID: 13444291143     PISSN: 1744165X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.siny.2004.10.001     Document Type: Review

References (101)

1. Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO). AIDS epidemic update: December 2003. Geneva: UNAIDS/WHO (Accessed at http://www.unaids.org/Unaids/EN/Resources/Publications/ corporate+publications/aids+epidemic+update+-+december+2003, May 1 2004).
2. N.A. Wade, G.S. Birkhead, B.L. Warren, T.T. Charbonneau, P.T. French, and L. Wang Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus N Engl J Med 339 1998 1409 1414
3. K.M. De Cock, M.G. Fowler, E. Mercier, I. de Vincenzi, J. Saba, and E. Hoff Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice JAMA 283 2000 1175 1182
4. E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, and M.J. O'Sullivan Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group N Engl J Med 331 1994 1173 1180
5. E.R. Cooper, M. Charurat, L. Mofenson, I. Hanson, J. Pitt, and C. Diaz Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission J Acquir Immune Defic Syndr 29 2002 484 494
6. European Collaborative Study Group HIV-infected pregnant women and vertical transmission in Europe since 1986 AIDS 15 2001 761 770
7. M. Lallemant, G. Jourdain, S. Le Coeur, S. Kim, S. Koetsawang, and A.M. Comeau A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators N Engl J Med 343 2000 982 991
8. N. Shaffer, M. Bulterys, and R.J. Simonds Short courses of zidovudine and perinatal transmission of HIV N Engl J Med 340 1999 1042 1043
9. S.Z. Wiktor, E. Ekpini, J.M. Karon, J. Nkengasong, C. Maurice, and S.T. Severin Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial Lancet 353 1999 781 785
10. F. Dabis, P. Msellati, N. Meda, C. Welffens-Ekra, B. You, and O. Manigart 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. DITRAME Study Group. DIminution de la Transmission Mere-Enfant Lancet 353 1999 786 792
11. J.B. Jackson, P. Musoke, T. Fleming, L.A. Guay, D. Bagenda, and M. Allen Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomized trial Lancet 362 2003 859 868
12. L.A. Guay, P. Musoke, T. Fleming, D. Bagenda, M. Allen, and C. Nakabiito Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial Lancet 354 1999 795 802
13. D. Moodley, J. Moodley, H. Coovadia, G. Gray, J. McIntyre, and J. Hofmyer A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1 J Infect Dis 187 2003 725 735
14. C. Crabb Breastfeeding and HIV transmission AIDS 17 2003 N13
15. R. Loebstein, A. Lalkin, and G. Koren Pharmacokinetic changes during pregnancy and their clinical relevance Clin Pharmacokinet 33 1997 328 343
16. M. Wadelius, E. Darj, G. Frenne, and A. Rane Induction of CYP2D6 in pregnancy Clin Pharmacol Ther 62 1997 400 407
17. M. Davis, C.J. Simmons, B. Dordoni, J.D. Maxwell, and R. Williams Induction of hepatic enzymes during normal human pregnancy J Obstet Gynaecol Br Commonw 80 1973 690 694
18. M.S. Yerby The use of anticonvulsants during pregnancy Semin Perinatol 25 2001 153 158
19. B.B. Little Pharmacokinetics during pregnancy: evidence-based maternal dose formulation Obstet Gynecol 93 1999 858 868
20. J.L. Mills Protecting the embryo from X-rated drugs N Engl J Med 333 1995 124 125
21. P. Lorenzi, V.M. Spicher, B. Laubereau, B. Hirschel, C. Kind, and C. rudin Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study AIDS 12 1998 F241 F247
22. European Collaborative Study Group Exposure to antiretroviral therapy in utero or early life: The health of uninfected children born to HIV-infected women JAIDS 32 2003 380 387
23. R.E. Tuomala, D.E. Shapiro, L.M. Mofenson, Y. Bryson, M. Culnane, and M.D. Hughes Antiretroviral therapy during pregnancy and the risk of an adverse outcome N Engl J Med 346 2002 1863 1870
24. H.D. Watts Management of human immunodeficiency virus infection in pregnancy N Engl J Med 346 2002 1879 1891
25. J.L. Martin, C.E. Brown, N. Matthews-Davis, and J.E. Reardon Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis Antimicrob Agents Chemother 38 1994 2743 2749
26. K. Brinkman, H.J. ter Hofstede, D.M. Burger, J.A. Smeitink, and P.P. Koopmans Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway AIDS 12 1998 1735 1744
27. S. Blanche, M. Tardieu, P. Rustin, A. Slama, B. Barret, and G. Firtion Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues Lancet 354 1999 1084 1089
28. M. Bulterys, S. Nesheim, E.J. Abrams, P. Palumbo, J. Farley, and M. Lampe Lack of evidence of mitochondrial dysfunction in the offspring of HIV-infected women. Retrospective review of perinatal exposure to antiretroviral drugs in the Perinatal AIDS Collaborative Transmission Study Ann N Y Acad Sci 918 2000 212 221
29. K. Dominguez, J. Bertolli, M. Fowler, I. Peters, S. Ortiz, and T. Melville Lack of definitive severe mitochondrial signs and symptoms among deceased HIV-uninfected and HIV-indeterminate children < or = 5 years of age, Pediatric Spectrum of HIV Disease project (PSD), USA Ann N Y Acad Sci 918 2000 236 246
30. M.L. Lindegren, P. Rhodes, L. Gordon, and P. Fleming Drug safety during pregnancy and in infants. Lack of mortality related to mitochondrial dysfunction among perinatally HIV-exposed children in pediatric HIV surveillance Ann N Y Acad Sci 918 2000 222 235
31. B. Barret, M. Tardieu, P. Rustin, C. Lacroix, B. Chabrol, and I. Desguerre Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort AIDS 17 12 2003 1769 1785
32. A. Alimenti, D.R. Burdge, G.S. Ogilvie, D.M. Money, and J.C. Forbes Lactic acidemia in human immunodeficiency virus-uninfected infants exposed to perinatal antiretroviral therapy Pediatr Infect Dis J 22 2003 782 789
33. M.P. Dube, and F.R. Sattler Metabolic complications of antiretroviral therapies AIDS Clin Care 10 1998 41 44
34. W. Powderly Long-term exposure to lifelong therapies JAIDS 29 2002 S28 S40
35. J.A. Ibdah, M.J. Bennett, and P. Rinaldo A Fetal Fatty-Acid Oxidation Disorder as a Cause of Liver Disease in Pregnant Women N Eng J Med 340 1999 1723 1731
36. Food and Drug Administration. Important drug warning: retyped text of a letter from Bristol-Myers Squibb, January 5, 2001.
37. L. Sarner, and A. Fakoya Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication Sexually Transmitted Infections 78 2002 58 59
38. J.O. Stern, P.A. Robinson, J. Love, S. Lanes, M.S. Imperiale, and D.L. Mayers A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients J Acquir Immune Defic Syndr 34 Suppl. 1 2003 S21 S33
39. S.J. Bersoff-Matcha, W.C. Miller, J.A. Aberg, C. van der Horst, H.J. Hamrick, and W.G. Powderly Sex differences in nevirapine rash Clin Infect Dis 32 2001 124 129
40. Lyons F, Hopkins S, McGeary A, Sheehan G, Bergin C, Mulcahy F, et al. Nevirapine tolerability in HIV infected women in pregnancy - A word of caution [abstract]. 2nd IAS conference on HIV pathogenesis and Treatment, Paris, 2003.
41. P. Langlet, M.-P. Guillaume, and J. Devriendt Fatal liver failure associated with nevirapine in a pregnant HIV patient: the first reported case Gastroentrol 118 Suppl. 2 2000 A6623
42. B. Ledergerber, M. Egger, M. Opravil, A. Telenti, B. Hirschel, and M. Battegay Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study Lancet 353 1999 863 868
43. R.L. Murphy, and J. Montaner Nevirapine: a review of its development, pharmacological profile and potential for clinical use Exp Opin Invest Drugs 5 1996 1183 1199
44. D.V. Havlir, S. Eastman, A. Gamst, and D.D. Richman Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients J Virol 70 1996 7894 7899
45. J.B. Jackson, G. Becker-Pergola, L.A. Guay, P. Musoke, M. Mracna, and M.G. Fowler Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission AIDS 14 2000 F111 F115
46. C.K. Cunningham, M.L. Chaix, C. Rekacewicz, P. Britto, C. Rouzioux, and R.D. Gelber Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316 J Infect Dis 186 2002 181 188
47. S.H. Eshleman, M. Mracna, L.A. Guay, M. Deseyve, S. Cunningham, and Mirochnick Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012) AIDS 15 2001 1951 1957
48. M.M. Parker, N. Wade, R.M. Lloyd Jr., G.S. Birkhead, B.K. Gallagher, and B. Cheku Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns J Acquir Immune Defic Syndr 32 2003 292 297
49. M.S. Hirsch, F. Brun-Vezinet, R.T. D'Aquila, S.M. Hammer, V.A. Johnson, and D.R. Kuritzkes Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel JAMA 283 2000 2417 2426
50. J.A. Sandberg, and W. Slikker Developmental pharmacology and toxicology of anti-HIV therapeutic agents: dideoxynucleosides Faseb J 9 1995 1157 1163
51. D.S. Stein, and K.H. Moore Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians Pharmacotherapy 21 2001 11 34
52. J.M. Collins, and J.D. Unadkat Clinical pharmacokinetics of zidovudine. An overview of current data Clin Pharmacokinet 17 1989 1 9
53. M.J. O'Sullivan, P.J. Boyer, G.B. Scott, W.P. Parks, S. Weller, and M.R. Blum The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group Am J Obstet Gynecol 168 1993 1510 1516
54. J. Moodley, D. Moodley, K. Pillay, H. Coovadia, J. Saba, and R. van Leeuwen Pharmacokinetics and antiretroviral activity of lamivudine alone or when co-administered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring J Infect Dis 178 1998 1327 1333
55. D.H. Watts, Z.A. Brown, T. Tartaglione, S.K. Burchett, K. Opheim, and R. Coombs Pharmacokinetic disposition of zidovudine during pregnancy J Infect Dis 163 1991 226 232
56. J.C. Pons, A.M. Taburet, E. Singlas, J.F. Delfraissy, and E. Papiernik Placental passage of azathiothymidine (AZT) during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound Eur J Obstet Gynecol Reprod Biol 40 1991 229 231
57. J.H. Rodman, P.M. Flynn, B. Robbins, E. Jiminez, A.D. Bardeguez, and J.F. Rodriguez Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants J Infect Dis 180 1999 1844 1850
58. C. Bhadrakom, R.J. Simonds, J.V. Mei, S. Asavapiyanont, V. Sangtaweesin, and N. Vanprapar Oral zidovudine during labor to prevent perinatal HIV transmission, Bangkok: tolerance and zidovudine concentration in cord blood. Bangkok Collaborative Perinatal HIV Transmission Study Group AIDS 14 2000 509 516
59. M. Mirochnick, E. Capparelli, and J. Connor Pharmacokinetics of zidovudine in infants: a population analysis across studies Clin Pharmacol Ther 66 1999 16 24
60. E.V. Capparelli, M. Mirochnick, W.M. Dankner, S. Blanchard, L. Mofenson, and G.D. McSherry Pharmacokinetics and tolerance of zidovudine in preterm infants J Pediatr 142 2003 47 52
61. K.M. Ayers, D. Clive, W.E. Tucker Jr., G. Hajian, and P. de Miranda Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats Fundam Appl Toxicol 32 1996 148 158
62. M.A. Johnson, K.H. Moore, G.J. Yuen, A. Bye, and G.E. Pakes Clinical pharmacokinetics of lamivudine Clin Pharmacokinet 36 1999 41 66
63. K.H. Moore, J.E. Barrett, S. Shaw, G.E. Pakes, R. Churchus, and A. Kapoor The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1 AIDS 13 1999 2239 2250
64. L. Mandelbrot, G. Peytavin, G. Firtion, and R. Farinotti Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women Am J Obstet Gynecol 184 2001 153 158
65. D. Moodley, K. Pillay, K. Naidoo, J. Moodley, M.A. Johnson, and K.H. Moore Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours J Clin Pharmacol 41 2001 732 741
66. E. Capparelli, M. Mirochnick, E.P. Acosta, K. Luzuriaga, Y. Bryson, and Wara D Lamuvidine Pharmacokinetics in Infants - A population analysis across studies [abstract] Pediatr Res 55 2004 328A
67. N.R. Hartman, R. Yarchoan, J.M. Pluda, R.V. Thomas, K.S. Marczyk, and S. Broder Pharmacokinetics of 2',3'-dideoxyadenosine and 2', 3'-dideoxyinosine in patients with severe human immunodeficiency virus infection Clin Pharmacol Ther 47 1990 647 654
68. G. Ahluwalia, D.A. Cooney, H. Mitsuya, A. Fridland, K.P. Flora, and Z. Hao Initial studies on the cellular pharmacology of 2',3'-dideoxyinosine, an inhibitor of HIV infectivity Biochem Pharmacol 36 1987 3797 3800
69. Y. Wang, E. Livingston, S. Patil, R.E. McKinney, A.D. Bardeguez, and J. Gandia Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus-infected pregnant women and their neonates: an AIDS clinical trials group study J Infect Dis 180 1999 1536 1541
70. C.M. Pereira, C. Nosbisch, H.R. Winter, W.L. Baughman, and J.D. Unadkat Transplacental pharmacokinetics of dideoxyinosine in pigtailed macaques Antimicrob Agents Chemother 38 1994 781 786
71. C. Rongkavilit, P. Thaithumyanon, T. Chuenyam, B.D. Damle, S. Limpongsanurak, and C. Boonrod Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates Antimicrob Agents Chemother 45 2001 3585 3590
72. K.Z. Rana, and M.N. Dudley Clinical pharmacokinetics of stavudine Clin Pharmacokinet 33 1997 276 284
73. F. Becher, R. Landman, S. Mboup, C. Kane, A. Canestri, and F. Liegeois Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients AIDS 18 2004 181 187
74. Wade N, Unadkat J, Huang S, Bryson Y, Yasin S, Mofenson L, et al. Pharmacokinetics and Safety of d4T and 3TC in HIV-infected Pregnant Women and Their Infants (PACTG 332) [abstract]. In: 10th Conference on Retroviruses and Opportunistic Infections, February 2003; Boston, MA; 2003.
75. R.E. Bawdon The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir Infect Dis Obstet & Gynecol 1998 1998 244 246
76. T. Tuntland, A. Odinecs, C.M. Pereira, C. Nosbisch, and J.D. Unadkat In vitro models to predict the in vivo mechanism, rate, and extent of placental transfer of dideoxynucleoside drugs against human immunodeficiency virus Am J Obstet Gynecol 180 1999 198 206
77. Public Health Service Task Force. Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy: March 23, 2004. (Accessed at http://www.aidsinfo.nih.gov/guidelines/perinatal/ST_032304.pdf, May 1, 2004)
78. K.K. Van Rompay, M.B. McChesney, N.L. Aguirre, K.A. Schmidt, N. Bischofberger, and M.L. Marthas Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection J Infect Dis 184 2001 429 438
79. M. Mirochnick, D.F. Clarke, and A. Dorenbaum Nevirapine: pharmacokinetic considerations in children and pregnant women Clin Pharmacokinet 39 2000 281 293
80. Lamson MJ Cort S, Macy H, Love J, Korplaski D, Pav J, et al. Effects of food or antacid on the bioavailability of nevirapine 200 mg in 24 healthy volunteers [abstract]. In: 11th World Conference on AIDS, 1996 July 7-12; Vancouver, Canada; 1996.
81. M. Mirochnick, S. Siminski, T. Fenton, M. Lugo, and J.L. Sullivan Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure Pediatr Infect Dis J 20 2001 803 805
82. J.S. Stringer, M. Sinkala, V. Chapman, E.P. Acosta, G.M. Aldrovandi, and V. Mudenda Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine AIDS 17 2003 1659 1665
83. M. Mirochnick, A. Dorenbaum, S. Blanchard, C.K. Cunningham, R.D. Gelber, and L. Mofenson Predose infant nevirapine concentration with the two-dose intrapartum neonatal nevirapine regimen: association with timing of maternal intrapartum nevirapine dose J Acquir Immune Defic Syndr 33 2003 153 156
84. A.K. Shetty, H.M. Coovadia, M.M. Mirochnick, Y. Maldonado, L.M. Mofenson, and L. Eshleman Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly, or weekly in breast-feeding infants from birth to 6 months J Acquir Immune Defic Syndr 34 2003 482 490
85. Public Health Service Task Force. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States - November 26, 2003 (Accessed at http://www.aidsinfo.nih.gov/guidelines/perinatal/ PER_112603.pdf, May 1, 2004).
86. R.P. van Heeswijk, A. Veldkamp, J.W. Mulder, P.L. Meenhorst, J.M. Lange, and J.H. Benjnen Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience Antivir Ther 6 2001 201 229
87. B.J. Aungst P-glycoprotein, secretory transport, and other barriers to the oral delivery of anti-HIV drugs Adv Drug Deliv Rev 39 1999 105 116
88. E.F. Choo, B. Leake, C. Wandel, H. Imamura, A.J. Wood, and G.R. Wilkinson Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes Drug Metab Dispos 28 2000 655 660
89. M. Mirochnick, A. Dorenbaum, D. Holland, B. Cunningham-Schrader, C. Cunningham, and M. Mirochnick Concentrations of protease inhibitors in cord blood after in utero exposure Pediatr Infect Dis J 21 2002 835 838
90. Viracept package insert 2000 Agouron-Pfizer Pharmacetuicals La Jolla CA
91. Bryson YJ, Stek A, Mirochnick M, Mofenson L, Connor J, Watts H, et al. Pharmacokinetics, antiviral activity and safety of nelfinavir (NFV) with ZDV/3TC in pregnant HIV-infected women and their infants: PACTG 353 Cohort 2 [abstract]. In: 9th Conference on Retroviruses and Opportunistic Infections, 2002 February; Seattle WA; 2002.
92. Mirochnick M, Bryson YJ, Stek A. Mofenson L, Connor JD, Watts H, et al. Pharmacokinetics (PK) of Nelfinavir (NFV) and its M8 Metabolite in Pregnant HIV-Infected Women and Their Infants: PACTG 353 [abstract]. In: Pediatric Academic Societies Meeting, 2003 May; Seattle, WA; 2003.
93. C. Rongkavilit, R.P. van Heeswijk, S. Limpongsanurak, P. Thaithumyanon, C. Boonrod, and A.M. Hassink Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates J Acquir Immune Defic Syndr 29 2002 455 463
94. Wara D, Tuomala R, Bryson Y, Unadkat J, Mofenson L, Smith E, et al. PACTG 358 - Safety, pharmacokinetics and antiretroviral activity of indinavir, zidovudine (ZDV) and lamuvidine (3TC) in HIV-1 seropositive pregnant women and infants [abstract]. In: Second Conference on Global Strategies for the Prevention of HIV Transmission from Mothers to Infants, 1999 September; Montreal, Canada; 1999.
95. B.W. Kosel, K.P. Beckerman, S. Hayashi, M. Homma, and F.T. Aweeka Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women AIDS 17 2003 1195 1199
96. S. Hayashi, K. Beckerman, M. Homma, B.W. Kosel, and F.T. Aweeka Pharmacokinetics of indinavir in HIV-positive pregnant women AIDS 14 2000 1061 1062
97. Fortovase package insert. Roche Laboratories; Nutley, NJ; 2000.
98. E.P. Acosta, C. Zorrilla, R. Van Dyke, A. Bardeguez, E. Smith, and M. Hughes Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women HIV Clin Trials 2 2001 460 465
99. V. Vithayasai, G.J. Moyle, V. Supajatura, N. Wattanatchanya, S. Kanshana, and P. Sirichthapom Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission J Acquir Immune Defic Syndr 30 2002 410 412
100. E.P. Acosta, A. Bardeguez, C.D. Zorrilla, R. Van Dyke, M.D. Hughes, and S. Huang Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women Antimicrob Agents Chemother 48 2004 430 436
101. Scott G, Rodman J, Scott W, Shapiro D, Huang S, Smith E, et al. Pharmacokinetic and virologic response to ritonavir (RTV) in combination with zidovudine (ZDV) and lamivudine (3TC) in HIV-1-infected pregnant women and their infants. [abstract] In: 9th Conference on Retroviruses and Opportunistic Infections, 2002 February; Seattle WA; 2002.